论文部分内容阅读
从最近美国食品药物管理局(FDA)“自动收回佐美酸钠(zomepizac sodium)”的通报电文获悉,用于轻度或中度疼痛的非甾体抗炎药佐美酸钠,因发现有严重过敏反应并已有5例引起死亡,美国已通知病人停止使用该药,将尚未使用的药品退回药房。据出售该药的 McNeil 药厂估计,自从该药上市以来,约有1500万人眼用过,除美国以外,在其它34个国
From a recent notification message from the U.S. Food and Drug Administration (FDA) that “zomepizac sodium is automatically withdrawn”, it has been reported that sodium nosoate, a non-steroidal anti-inflammatory drug for mild or moderate pain, Serious allergic reactions and 5 deaths have already been reported. The United States has informed patients to stop using the drug and return unused drugs to the pharmacy. According to McNeil Pharmaceuticals, which sells the drug, about 15 million people have used it since the drug went public, with the exception of the United States in 34 other countries